Patient Square Capital

LXE Hearing is a company focused on championing hearing wellness for everyone, everywhere. The company's mission is to revolutionize hearing wellness through innovation, ensuring access to affordable, life-enhancing solutions.

Patterson Companies, Inc. is a leading distributor of dental and animal health products, operating primarily in the United States, with additional markets in the United Kingdom and Canada. The company is structured into three segments: Dental, Animal Health, and Corporate. The Dental segment supplies a wide range of consumable products, dental equipment, and technology solutions, alongside various services such as maintenance and financing. The Animal Health segment focuses on distributing pharmaceuticals, vaccines, diagnostics, and nutritional products, while also offering private label items under established brands. The Corporate segment provides customer financing services and miscellaneous products. Patterson Companies serves a diverse clientele that includes dentists, laboratories, veterinarians, and other healthcare professionals. Founded in 1877 and headquartered in Saint Paul, Minnesota, the company was originally known as Patterson Dental Company before rebranding in 2004.

CorroHealth is a company that focuses on healthcare analytics and technology solutions aimed at enhancing revenue cycle management for healthcare systems. By using advanced analytics and proprietary artificial intelligence, CorroHealth seeks to improve the financial performance of hospitals and healthcare facilities. The company also offers reimbursement cycle tracking services, addressing regulatory and compliance challenges while integrating revenue cycle technologies. This approach not only alleviates burdens on physicians but also aims to improve financial outcomes for both healthcare providers and payers.

Nuclera specializes in providing a protein prototyping system designed to enhance drug discovery by making proteins readily accessible to researchers. The company's eProtein Discovery system enables scientists to quickly produce and evaluate proteins, thus accelerating their research efforts. Nuclera's automated platform delivers reliable, high-quality, and soluble proteins within a specified timeframe, facilitating the scale-up of protein projects. The integration of technology, including cell-free protein synthesis and digital microfluidics on smart cartridges, allows for efficient, high-throughput access to proteins. This streamlined approach supports researchers in advancing their protein projects more rapidly and effectively.

GondolaBio researches, develops and manufactures pharmaceutical products.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.

Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.

Elevage Medical Technologies is a company focused on advancing the development of medical devices and therapeutic solutions aimed at improving health outcomes and quality of life for patients. By providing both financial support and strategic guidance, Elevage assists life science and medical device companies in enhancing their therapeutic pipelines. The company's commitment lies in fostering innovation within the healthcare sector, enabling these companies to develop and accelerate novel therapies. Through its efforts, Elevage seeks to transform healthcare and deliver meaningful improvements in patient health.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's technology offers a comprehensive, high-resolution view of subcellular gene expression activities, which is crucial for advancements in various fields such as oncology, neuroscience, and infectious diseases. Resolve BioSciences provides a range of services and expertise in bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among other areas. This innovative approach supports researchers in their efforts to explore complex biological systems and improve outcomes in health and agriculture.

Hanger, Inc. is a leading provider of orthotic and prosthetic (O&P) services and products, focusing on enhancing or restoring the physical capabilities of patients with disabilities or injuries. Based in Austin, the company operates through two main segments: Patient Care and Products and Services. The Patient Care segment includes Hanger Clinic, which designs, fabricates, and delivers custom O&P devices across over 700 clinics. The Products and Services segment offers distribution and therapeutic solutions to various businesses. Hanger is recognized for its advanced prosthetics and orthotics, patient-focused approach, and commitment to clinical excellence by integrating emerging technologies into its practices.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.

Enavate Sciences is committed to investing in and supporting the strategic growth of innovative therapeutic and enabling technology companies.

Access TeleCare is a provider of acute care telemedicine and technology services aimed at hospitals, health systems, post-acute providers, and physician networks. The company specializes in a range of clinical specialties, including telecardiology, teleneurology, telepsychiatry, telepulmonology, telehospitalists, teleinfectious disease, and telematernal fetal medicine. By leveraging advanced technology, Access TeleCare facilitates virtual patient care, helping healthcare organizations develop sustainable telemedicine programs. Their comprehensive offerings enable healthcare providers to enhance patient access to specialized care and improve overall healthcare delivery.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

Summit Behavioral Healthcare is an Atlanta-based provider of addiction treatment and behavioral health services. It was established to develop and operate a network of leading behavioral health centers throughout the country. Summit BHC’s sole focus is on the provision and management of specialty chemical dependency and addiction disorder services within a flexible and dynamic continuum of care. Their treatment facilities are specialized solely in helping adults and families suffering from addiction to alcohol and other drugs while offering a solution to the stressors that drive the addiction, providing a path to change and ensuring ongoing support for a restored life.

Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.